Whereas, it still remains unknown whether DR4 and DR5 targeting therapeutics will meet the requirements to get approval for cancer therapy, a number of these novel formulations raise hope, due to the excellent results obtained from preclinical or early clinical studies. Here, TNFRSF10B is linked to cancer.